The KLOW peptide blend is becoming a popular focus for research. The liquid comes out blue, which is normal, even though most other peptides reconstitute clear. I've personally been researching it, so I wanted to post a simple explainer of what is in the vial, why it is blue, and what the published literature does and does not say, along with my own research findings so far.

What's in a KLOW vial

KLOW is four peptides blended together into one vial. The name is just the ingredients: GLOW is GHK-Cu, BPC-157 and TB-500, and adding KPV makes it KLOW.

A standard KLOW vial is 80 mg, labeled 50/10/10/10:

Compound	Amount	Share of vial
GHK-Cu	50 mg	62.5%
BPC-157	10 mg	12.5%
TB-500	10 mg	12.5%
KPV	10 mg	12.5%

Note: Almost two thirds of the vial by weight is GHK-Cu.

Why Klow is blue

The blue is the copper in GHK-Cu. Real chemistry, not a dye.

GHK on its own is colorless. Add a copper ion and the peptide wraps around it and holds it in place. Copper held that way soaks up light in the red-orange range. Whatever a substance soaks up, you see the opposite color, so it looks blue.

Blue means the copper is bound. No copper, no color. So the blue is a free visual check that you have an actual copper complex in there.

The dry powder usually looks pale blue or light-blue rather than vivid. The color becomes much more pronounced once its reconstituted in liquid.

What the research shows for the KLOW peptide

GHK-Cu (skin). A tiny three-amino-acid peptide holding a copper ion. Found naturally in human blood, first pulled out of serum in 1973 and confirmed to be glycyl-histidyl-lysine four years later.[1][2] In fibroblast culture and rat wound studies it increased collagen production and the sugar-protein molecules that organize collagen into proper structure, though not everything moved together: decorin went up, biglycan went down.[3][4] Human skin cells showed the same rise in those structural sugars.[5] A 2014 re-analysis of gene expression data found it shifted about a third of the genes assayed, roughly 4,200, a lot of them tied to repair and antioxidant defense.[6] This is the best-supported compound in the blend, and most of the strongest human data is from topical skincare research rather than subQ.

BPC-157 (blood supply). A synthetic 15-amino-acid chain taken from a larger protein found in stomach fluid.[7] In rats with restricted blood flow and in cultured blood vessel cells, it turned up and activated a receptor called VEGFR2 that drives the growth of new blood vessels.[8] Simply: it seems to help build new blood supply into damaged tissue, and blood supply is usually the bottleneck in tendon repair. Human evidence is three small pilot trials, nothing rigorous.[9]

TB-500 (cell movement). Also called "thymosin beta-4", a protein cells use to build and rearrange their internal scaffolding. In cell and tissue assays it drove blood vessel cell migration, adhesion, and vessel sprouting, and in rat wounds it sped skin closure by 42% at four days and up to 61% at seven days versus saline controls.[10][11] If BPC-157 builds the road, TB-500 gets the repair crew moving down it.

KPV (inflammation). Three amino acids clipped off the end of a hormone called alpha-MSH. It keeps the anti-inflammatory part and skips the pigment signaling, because unlike the parent hormone it does not work through melanocortin receptors.[12][13] It works inside the cell, turning down NF-kB, which is basically the master switch for inflammation.[14] In mice with induced gut inflammation it reduced inflammation, weight loss, and immune cell infiltration.[15]

The components have limited, to no human trials. However, the FDA just voted to "recommend" BPC-157, TB-500, and KPV. I made a post on what that means here: https://www.reddit.com/r/ScienceBioTechnology/s/2VJTiw9RSP

No published research on KLOW

Every study above tested one compound alone. There is no published research on KLOW as a formulation. The logic for combining them is that each targets a different step of the same repair process, and that logic is reasonable. It also can help researchers utilize all four compounds at once, which is more convenient. However, reasonable logic is not proven science.

KLOW reconstitution: Why "units" on its own means nothing

This is the most confused thing in every KLOW thread.

A U-100 insulin syringe has 100 units across 1 mL, so one unit is 0.01 mL. That is a volume, not an amount of peptide. Until you say how much water went into the vial, "15 units" means nothing.

Same 80 mg vial, three different reconstitution volumes:

BAC water added	Concentration	1 unit	10 units	15 units
2 mL	40 mg/mL	0.4 mg	4 mg	6 mg
2.5 mL	32 mg/mL	0.32 mg	3.2 mg	4.8 mg
3 mL	26.7 mg/mL	0.267 mg	2.67 mg	4 mg

Fifteen units is anywhere from 4 mg to 6 mg depending only on how much water you added. Research amounts are always in mg or mcg, never units.

Write the volume and the date somewhere when you mix it. In three weeks you may not remember.

My research log, 5 weeks in

Five weeks total, currently partway through a second 4 week research cycle with a short gap between them.

• 3 mL of bacteriostatic water into 80 mg vial, so 26.7 mg/mL
• Working amount 15 units (5 days on 2 off), which is 4 mg of total blend
• At the 50/10/10/10 split that is 2.5 mg GHK-Cu and 0.5 mg each of BPC-157, TB-500 and KPV

Personally using it for skin research. Positive texture and tone changes were visible by the back half of the first cycle and have kept improving through the second. Fewer breakouts as well, and the ones that do show up settle faster than baseline. Visible inflammation seems to be coming down too.

Not a surprising result, given GHK-Cu is 62.5% of the vial and skin remodeling is exactly where GHK-Cu has the most supporting data.[3][4][5]

First-time researcher mistakes

• Firing the water straight into the powder. Aim down the inside wall and go slow. Foaming means you are stressing it. (I do this by accident sometimes, not going to ruin the compound but you want to try and avoid it).
• Shaking it. Just gently swirl and wait.
• Panicking at the blue. It is supposed to be blue.
• Using plain sterile water instead of bacteriostatic. The 0.9% benzyl alcohol in BAC water is what keeps the vial usable after repeated punctures.
• Not writing the mix date and reconstitution volume down.
• Not refrigerating it after reconstitution.

Sources

Everything above, in order. All on PubMed if you want to read them yourself.

1. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nature New Biology. 1973;243(124):85-7. PMID 4349963
2. Schlesinger DH, Pickart L, Thaler MM. Growth-modulating serum tripeptide is glycyl-histidyl-lysine. Experientia. 1977;33(3):324-5. PMID 858356
3. Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 1988;238(2):343-6. PMID 3169264
4. Siméon A, Wegrowski Y, Bontemps Y, Maquart FX. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). Journal of Investigative Dermatology. 2000;115(6):962-8. PMID 11121126
5. Wegrowski Y, Maquart FX, Borel JP. Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. Life Sciences. 1992;51(13):1049-56. PMID 1522753
6. Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: resetting the human genome to health. BioMed Research International. 2014;2014:151479. PMID 25302294
7. Sikirić P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of Physiology Paris. 1993;87(5):313-27. PMID 8298609
8. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323-333. PMID 27847966
9. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025;18(12):611-619. PMID 40789979
10. Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB Journal. 2003;17(14):2103-5. PMID 14500546
11. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. 1999;113(3):364-8. PMID 10469335
12. Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB Journal. 1989;3(11):2282-4. PMID 2550304
13. Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. Journal of Pharmacology and Experimental Therapeutics. 2003;306(2):631-7. PMID 12750433
14. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78. PMID 18061177
15. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324-31. PMID 18092346

Disclaimer: Klow is for research use only. Not FDA-approved, not for human consumption, sold for laboratory research use only. Researchers are responsible for compliance with their own local rules. Nothing here is medical advice.

Happy to answer follow-ups.